-
EH/CAH eCQMs - Eligible Hospitals/Critical Access Hospitals
-
Resolution: Answered
-
Moderate
-
None
-
None
-
Peggy Lutz
-
715-305-7805
-
Ascension WI
-
-
CMS0506v5
We are seeking clarification on CMS 506 Safe Use of Opioids, Concurrent Prescribing, particularly the denominator exclusion related to cancer diagnosis.
According to Epic's Green Book (April 28, 2023) measure specifications for the 2023 reporting year, it is a denominator exclusion for inpatient hospitalization where patients have cancer that overlaps the encounter.
What determines if the cancer diagnosis overlaps the encounter?
- Does the cancer diagnosis have to be a coded diagnosis for the encounter to be considered an exclusion?
- If the cancer diagnosis is on the non-hospital problem list, is it considered an exclusion?
- Is there a timeframe from the date of IP encounter where cancer diagnosis would qualify as overlapping and be an exclusion?
Here is an example of an encounter where I questioned if the cancer diagnosis should be considered a denominator exclusion.
Here is another example where this time cancer is listed as a denominator exclusion where I cannot find evidence of a cancer diagnosis.
Admit date 10/6/2023 Discharge date 10/30/2023
CMS-506 - denominator exclusion
Chart review: Intra-abdominal abscess (HCC) is the only hospital problem listed. I do not see a diagnosis of cancer on the non-hospital problem list. The only thing I found in the chart is familial cancer of breast listed on the hospital non-problem list. Coding does not show a diagnosis code for cancer for the inpatient encounter.
- Does familial cancer overlapping the encounter qualify for denominator exclusion?
Below are copies of the problem list and Epic mapping related to this metric.
In Epic's Green Book for Measure Logic (2022 Reporting Year), it is a denominator exclusion when the patient has a diagnosis of cancer (all primary and secondary cancer) at any time during the hospitalization. This was easy to identify from the hospital problem list and coding.